New Triple-Drug attack targets tough leukemia

NCT ID NCT06782542

Recruiting now Disease control Sponsor: Justin Watts, MD Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing a combination of three drugs—olutasidenib, venetoclax, and azacitidine—in adults aged 18-75 with newly diagnosed acute myeloid leukemia that has a specific IDH1 gene mutation. The study aims to see if this combo is safer and works better than standard intensive chemotherapy. Sixteen participants will be enrolled to check for side effects and how many achieve complete remission.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: olutasidenib, venetoclax, and azacitidine
What this could lead to: If successful, this combination could offer a more effective and tolerable treatment option for people with a specific genetic subtype of acute myeloid leukemia.
What could go wrong: This is a small, early-phase study (16 participants) focused on safety and initial effectiveness. The combination may cause significant side effects and may not prove better than standard chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA IDH1 MUTATION

Contacts and locations

Locations

University of Miami
RECRUITING

Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.